Shifting phase
Ruyanic exists to close the gap between a therapeutic that works in theory and one a patient can actually, reliably take.
Every year, therapeutics with proven efficacy underperform in the real world — not because the molecule failed, but because the format did. A swallow is assumed. Water is assumed. A patient who can, and will, take the dose is assumed. We design for the people those assumptions leave behind.
Three patient realities that conventional oral and injectable formats were never designed to hold — and that Instasolv was.
A child who cannot — or will not — swallow a tablet is not non-compliant. They are failed by the format. Instasolv Film and Tablet dissolve on contact, removing the swallowing barrier and the taste rejection that sends a working dose into the sink.
Swallowing difficulty is common in aging and neurological disease, and it turns a daily medication into a risk. Instasolv needs no water and no swallow — a dose designed for people whose bodies have already been asked enough.
Too many therapies arrive in formats designed for someone else. Instasolv Vaginal, built on Phasys, opens both localized and systemic delivery through mucosal tissue — meeting the physiology, and the patient, on their own terms.
Water, swallowing, and injection are the quiet reasons doses get skipped. Remove them from the ritual, and a therapy that already works has a chance to work in someone’s actual life.
A non-invasive alternative when the clinical need does not require a needle — and the patient should never have to accept one by default.
Direct mucosal absorption can bypass GI transit and first-pass metabolism, opening a path to faster, more predictable onset than a swallow-and-wait tablet.
We’re looking for pharmaceutical partners, biotech innovators, and investigators ready to put Instasolv to work on their next molecule.